In Studies 2 (NCT#03548935), 3 (NCT#03552757), and 4 (NCT#03611582), WEGOVY or matching placebo was escalated to 2.4 mg subcutaneous weekly during a 16-week period followed by 52 weeks on maintenance dose
Rathinam et al
The SURMOUNT trials showed tirzepatide at 15 mg producing over 22% body weight loss on average, compared to roughly 15% for semaglutide 2.4 mg in the STEP trials
Each serving contains 100mg of collagen, a key protein that helps maintain skin elasticity and firmness
63 An essential component to managing cutaneous disease in SLE is prevention, with aggressive sun-protective measures including protective clothing, avoiding exposure during peak sunlight hours, and daily use of SPF 70 or higher broad-spectrum ultraviolet A/B sunscreens
R., Hartoft-Nielsen, M.-L., Hansen, O